Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - What's Next?

Key Points

• Immatics shares experienced a sharp surge in trading activity, with volume rising 215% to 1.5 million shares; the stock last traded at $8.31 versus a prior close of $8.60.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $20.60 price target, although ratings range from Buy to Sell.
• The company reported weaker-than-expected quarterly results, including a loss of $0.53 per share versus an expected $0.47 loss and revenue of $10.44 million against a $12.42 million estimate; meanwhile, Perceptive Advisors increased its position by 8.31%.

Immatics N.V. (NASDAQ:IMTX - Get Free Report) shares saw strong trading volume on Thursday . 1,505,059 shares were traded during trading, an increase of 215% from the previous session's volume of 477,598 shares.The stock last traded at $8.31 and had previously closed at $8.60.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immatics in a research note on Friday, September 18th. Jefferies Financial Group set a $17.00 price target on Immatics in a research note on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immatics has an average rating of "Moderate Buy" and a consensus price target of $20.60.

Immatics Stock Performance

The company has a 50-day moving average of $9.17 and a 200-day moving average of $9.90. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -4.41 and a beta of 1.33.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.06). Immatics had a negative return on equity of 47.41% and a negative net margin of 495.71%.The company had revenue of $10.44 million for the quarter, compared to analysts' expectations of $12.42 million. As a group, analysts expect that Immatics N.V. will post -2 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Perceptive Advisors Llc bought 863,060 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was purchased at an average price of $8.69 per share, with a total value of $7,499,991.40. Following the purchase, the director owned 11,246,516 shares of the company's stock, valued at $97,732,224.04. This trade represents a 8.31% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 3.30% of the company's stock.

Hedge Funds Weigh In On Immatics

Institutional investors have recently modified their holdings of the company. Sofinnova Investments Inc. lifted its stake in shares of Immatics by 54.2% during the fourth quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company's stock valued at $36,073,000 after buying an additional 1,207,705 shares during the period. Perceptive Advisors LLC raised its holdings in Immatics by 10.7% in the 4th quarter. Perceptive Advisors LLC now owns 10,383,456 shares of the company's stock valued at $109,026,000 after acquiring an additional 1,000,000 shares during the last quarter. Troluce Capital Advisors LLC purchased a new position in shares of Immatics during the 1st quarter worth $2,460,000. Monashee Investment Management LLC acquired a new stake in shares of Immatics during the fourth quarter worth $1,684,000. Finally, Wellington Management Group LLP grew its position in shares of Immatics by 5.5% in the second quarter. Wellington Management Group LLP now owns 1,647,852 shares of the company's stock valued at $16,693,000 after purchasing an additional 85,960 shares during the period. Institutional investors and hedge funds own 64.41% of the company's stock.

Immatics Company Profile

Immatics N.V. is a biopharmaceutical company focused on developing T cell receptor (TCR)-based therapies for cancer. The company aims to identify cancer targets that are presented on the surface of tumor cells and develop treatments that enable T cells to recognize and attack those cells, including targets that may be difficult to address with conventional antibody-based medicines.

Immatics' technology platforms support two primary approaches: TCR-engineered T-cell therapies, known as TCR-T, and TCR-based bispecific molecules designed to direct patients' T cells toward tumor cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.